A multicenter, single-arm, phase II clinical trial of Apatinib in combination with Vinorelbine as second line treatment for patients with advanced triple-negative breast cancer
Latest Information Update: 03 Dec 2020
At a glance
- Drugs Rivoceranib (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 03 Dec 2020 New trial record